Lanthionine synthetase component C-like proteins as molecular targets for preventing and treating diseases and disorders
| dc.contributor.assignee | Virginia Tech Intellectual Properties, Inc. | en |
| dc.contributor.inventor | Bassaganya-Riera, Josep | en |
| dc.contributor.inventor | Hontecillas, Raquel | en |
| dc.contributor.inventor | Lu, Pinyi | en |
| dc.date.accessed | 2016-08-19 | en |
| dc.date.accessioned | 2016-08-24T17:55:26Z | en |
| dc.date.available | 2016-08-24T17:55:26Z | en |
| dc.date.filed | 2011-05-04 | en |
| dc.date.issued | 2015-08-11 | en |
| dc.description.abstract | The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs. This includes but it is not limited to abscisic acid (ABA), ABA analogs, benzimidazophenyls, repurposed drugs or drug combinations, including thiazolidinediones (TZDs); naturally occurring compounds such as conjugated diene fatty acids, conjugated triene fatty acids, isoprenoids, and natural and synthetic agonists of peroxisome proliferator-activated receptors that activate this receptor through an alternative mechanism of action involving LANCL2 or other membrane proteins to treat or prevent the common inflammatory pathogenesis underlying type 2 diabetes, atherosclerosis, cancer, some inflammatory infectious diseases such as influenza and autoimmune diseases including but not limited to inflammatory bowel disease (Crohn's disease and Ulcerative colitis), rheumatoid arthritis, multiple sclerosis and type 1 diabetes and other chronic inflammatory conditions. | en |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.applicationnumber | 13100795 | en |
| dc.identifier.patentnumber | 9101573 | en |
| dc.identifier.uri | http://hdl.handle.net/10919/72758 | en |
| dc.identifier.url | http://pimg-fpiw.uspto.gov/fdd/73/015/091/0.pdf | en |
| dc.language.iso | en_US | en |
| dc.publisher | United States Patent and Trademark Office | en |
| dc.subject.cpc | A61K31/13 | en |
| dc.subject.cpc | A61K31/135 | en |
| dc.subject.cpc | A61K31/35 | en |
| dc.subject.cpc | A61K31/352 | en |
| dc.subject.cpc | A61K31/40 | en |
| dc.subject.cpc | A61K31/405 | en |
| dc.subject.cpc | A61K31/4184 | en |
| dc.subject.cpc | A61K31/427 | en |
| dc.subject.cpc | A61K31/431 | en |
| dc.subject.cpc | A61K31/495 | en |
| dc.subject.cpc | A61K31/496 | en |
| dc.subject.cpc | A61K31/4985 | en |
| dc.subject.cpc | A61K31/517 | en |
| dc.subject.cpc | A61K31/545 | en |
| dc.subject.cpc | A61K31/55 | en |
| dc.subject.cpc | A61K31/56 | en |
| dc.subject.cpc | A61K31/57 | en |
| dc.subject.cpc | A61K31/65 | en |
| dc.subject.cpc | A61K31/655 | en |
| dc.subject.cpc | A61K31/704 | en |
| dc.subject.cpc | A61K31/7048 | en |
| dc.subject.cpc | A61K2300/00 | en |
| dc.subject.cpc | G01N33/6872 | en |
| dc.subject.cpc | G01N33/573 | en |
| dc.subject.cpc | G01N33/6875 | en |
| dc.subject.cpc | G01N2333/4703 | en |
| dc.subject.cpc | G01N2333/70567 | en |
| dc.subject.cpc | G01N2500/02 | en |
| dc.subject.cpc | G01N2500/04 | en |
| dc.subject.cpc | G01N2500/20 | en |
| dc.subject.cpc | G06F19/12 | en |
| dc.subject.cpc | G06F19/16 | en |
| dc.subject.cpc | G06F19/3456 | en |
| dc.subject.cpc | Y10T436/14333 | en |
| dc.subject.cpc | Y10T436/14555 | en |
| dc.subject.cpc | Y10T436/14777 | en |
| dc.subject.uspc | 1/1 | en |
| dc.title | Lanthionine synthetase component C-like proteins as molecular targets for preventing and treating diseases and disorders | en |
| dc.type | Patent | en |
| dc.type.dcmitype | Text | en |
| dc.type.patenttype | utility | en |
Files
Original bundle
1 - 1 of 1